Charles Moon, MD
Orthopaedic Surgery · Los Angeles, CANPI 1376527440
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.3%), travel and lodging and royalties or licence payments — rather than concentrated in one kind of arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 21.8%. Among orthopaedic surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 859 payments — averaging $884.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Globus Medical$166K
- Si-bone, Inc.$150K
- Stryker$125K
- Paragon 28, Inc.$98K
- Acumed LLC$44K
- US Implant Solutions, LLC$40K
- plus $137K from 33 others
Across 46 payments — averaging $4912.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stryker$108K
- DJO, LLC$63K
- BONE Support AB$28K
- Illuminoss Medical, Inc.$27K
What the payments were for
- Royalty or licence$90,74212%
- Consulting fees$450,19459%
- Speaking & faculty fees$35,4255%
- Travel & lodging$151,17420%
- Food & beverage$31,0444%
- Education$1,2000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Globus Medical | 127 | $165,840 |
| Si-bone, Inc. | 155 | $150,391 |
| Stryker | 222 | $124,777 |
| Paragon 28, Inc. | 64 | $97,579 |
| Acumed LLC | 78 | $43,769 |
| US Implant Solutions, LLC | 29 | $40,380 |
| Extremity Medical | 18 | $39,486 |
| Bone Support Inc. | 23 | $26,802 |
| Corentec America Inc | 11 | $26,177 |
| My01 Inc. | 16 | $13,542 |
| Surgalign Spine Technologies, Inc. | 2 | $6,583 |
| Medical Device Business Services, Inc. | 7 | $5,581 |
| Illuminoss Medical, Inc. | 10 | $3,551 |
| Synthes GmbH | 4 | $3,439 |
| Osteocentric Technologies, Inc. | 14 | $3,259 |
| Arthrex | 14 | $2,620 |
| Zimmer Biomet | 21 | $2,302 |
| Medacta USA, Inc. | 7 | $836 |
| Nuvasive Specialized Orthopedics, Inc. | 4 | $475 |
| Integra Lifesciences Corporation | 3 | $361 |
| Micromed Inc | 3 | $271 |
| Lima USA, Inc. | 2 | $241 |
| Advanced Orthopaedic Solutions, Inc. | 2 | $222 |
| Johnson & Johnson(2 entities) | 4 | $174 |
| Biocomposites Inc | 2 | $132 |
| BD | 1 | $126 |
| Baxter Healthcare | 1 | $120 |
| Carbofix Orthopedics Inc | 1 | $108 |
| Argentum Medical | 1 | $104 |
| Next Science LLC | 1 | $83 |
| Smith+Nephew | 2 | $74 |
| Skeletal Dynamics Inc | 1 | $73 |
| Innovation Technologies Inc | 1 | $71 |
| Medtronic | 3 | $68 |
| Davol Inc. | 1 | $48 |
| Orthofix Medical, Inc. | 1 | $34 |
| Acera Surgical, Inc. | 1 | $33 |
| Vertex | 1 | $29 |
| Dynasplint Systems Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Portfolio$88,293
- iFuse Implant$76,707
- IFUSE IMPLANT SYSTEM$69,913
- A/R Femoral Nail$52,483
- T2$43,178
- AXSOS$40,317
- Omni Stable AF$37,907
- GAMMA$28,096
- CERAMENTBONE VOID FILLER$26,552
- Corentec$26,177
- Nitinail$24,463
- T2 ALPHA$24,413
- CERAMENT G$24,302
- ACUMED$22,876
- Suture Button Fixation$21,969
- Clavical Fixation (16-186)$15,898
- MY01 Continuous Compartmental Pressure Monitor$13,310
- TROCH NAIL$11,770
- Retrograde Fem Nail$11,400
- PRO$11,204
How this compares
$759,780 in reported general payments places this provider in the 95th percentile of 1,808 orthopaedic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 42 | $296 |
| Meloxicam | 27 | $182 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $76 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Los Angeles
- Kelly VinceLos Angeles$9.6M
- Jay LiebermanLos Angeles$4.8M
- Thomas SchmalzriedLos Angeles$4M
- David SkaggsLos Angeles$2.6M
- David ThordarsonLos Angeles$2.5M
- Edward McPhersonLos Angeles$1.2M
- Daniel AllisonLos Angeles$1.1M
- Justin SalimanLos Angeles$912K
- Andrew SpitzerLos Angeles$738K
- Yashar JavidanLos Angeles$685K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.